MRNA-1083 by Moderna for Influenzavirus B Infections: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenzavirus B Infections.
Sat.Nov 18, 2023
130 
SLAS 2024 International Conference and Exhibition
Drug Discovery World
NOVEMBER 18, 2023
SLAS 2024 International Conference and Exhibition will take place in Boston, MA, US from 3-7 February 2024.
Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
LuAG-09222 by H. Lundbeck for Migraine: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
LuAG-09222 is under clinical development by H. Lundbeck and currently in Phase II for Migraine.
Which pharmaceutical companies have the most drug patents in Russian Federation?
Drug Patent Watch
NOVEMBER 18, 2023
This chart shows the pharmaceutical companies with the most patents in Russian Federation. Patents must be filed in each country (or, in some cases regional patent office) where patent protection… The post Which pharmaceutical companies have the most drug patents in Russian Federation? appeared first on DrugPatentWatch - Make Better Decisions.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Risk adjusted net present value: What is the current valuation of TScan Therapeutics’s TSC-200-A0201?
Pharmaceutical Technology
NOVEMBER 18, 2023
TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.
Risk adjusted net present value: What is the current valuation of TScan Therapeutics’s TSC-200-A0201?
Pharmaceutical Technology
NOVEMBER 18, 2023
TSC-200-A0201 is a gene-modified cell therapy commercialized by TScan Therapeutics, with a leading Phase I program in Metastatic Ovarian Cancer.
Risk adjusted net present value: What is the current valuation of Rocket Pharmaceuticals’s RPA-501?
Pharmaceutical Technology
NOVEMBER 18, 2023
RPA-501 is a gene therapy commercialized by Rocket Pharmaceuticals, with a leading Phase II program in Glycogen Storage Disorders (GSD).
Rilzabrutinib by Principia Biopharma for Acquired (Autoimmune) Hemolytic Anemia: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Rilzabrutinib is under clinical development by Principia Biopharma and currently in Phase II for Acquired (Autoimmune) Hemolytic Anemia.
Commercial Drug Sourcing for Clinical Trials
Advertisement
The sourcing of commercial drugs for use in clinical trials either as a comparator, rescue or co-medication can be a complex process. Sponsors can face a number of challenges when trying to obtain these critical supplies for their studies, including addressing product lead times, availability, expiry limitations, safety and cost, among others. Choosing the right partner with global sourcing, regulatory, quality and clinical packaging expertise can provide the necessary guidance to help sponsors
Mirikizumab by Eli Lilly and Co for Crohn’s Disease (Regional Enteritis): Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Mirikizumab is under clinical development by Eli Lilly and Co and currently in Phase III for Crohn's Disease (Regional Enteritis).
Risk adjusted net present value: What is the current valuation of Celltrion’s Aflibercept Biosimilar.?
Pharmaceutical Technology
NOVEMBER 18, 2023
Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.
Risk adjusted net present value: What is the current valuation of Celltrion’s Aflibercept Biosimilar.?
Pharmaceutical Technology
NOVEMBER 18, 2023
Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.
Tusamitamab ravtansine by Sanofi for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma).
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
APHD-012 by Aphaia Pharma for Pre-Diabetes/Impaired Glucose Tolerance: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
APHD-012 is under clinical development by Aphaia Pharma and currently in Phase II for Pre-Diabetes/Impaired Glucose Tolerance.
MRNA-1083 by Moderna for Influenza A Virus, H1N1 Subtype Infections: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H1N1 Subtype Infections.
MRNA-1083 by Moderna for Influenza A Virus, H3N2 Subtype Infections: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-1083 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections.
Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?
Pharmaceutical Technology
NOVEMBER 18, 2023
Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.
Making the Case for Case Management for Cell and Gene Therapies
Advertisement
As demand for advanced therapies increases, so does the need for more specialized supply chain support, as these products have strict transportation and handling requirements. Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.
Risk adjusted net present value: What is the current valuation of F. Hoffmann-La Roche’s Basmisanil?
Pharmaceutical Technology
NOVEMBER 18, 2023
Basmisanil is a small molecule commercialized by F. Hoffmann-La Roche, with a leading Phase II program in Dup15q Syndrome.
Risk adjusted net present value: What is the current valuation of Kymera Therapeutics’s KT-413?
Pharmaceutical Technology
NOVEMBER 18, 2023
KT-413 is a small molecule commercialized by Kymera Therapeutics, with a leading Phase I program in Primary CNS Lymphoma.
Risk adjusted net present value: What is the current valuation of Bavarian Nordic’s PXVX-0317?
Pharmaceutical Technology
NOVEMBER 18, 2023
PXVX-0317 is a subunit vaccine commercialized by Bavarian Nordic, with a leading Phase III program in Chikungunya Fever.
BB-1701 by Bliss Biopharmaceutical (Hangzhou) for Solid Tumor: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Solid Tumor.
Deliver Fast, Flexible Clinical Trial Insights with Spotfire
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Risk adjusted net present value: What is the current valuation of Biomea Fusion’s Icovamenib?
Pharmaceutical Technology
NOVEMBER 18, 2023
Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.
Risk adjusted net present value: What is the current valuation of Biomea Fusion’s Icovamenib?
Pharmaceutical Technology
NOVEMBER 18, 2023
Icovamenib is a small molecule commercialized by Biomea Fusion, with a leading Phase II program in Type 2 Diabetes.
Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-3705?
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.
Risk adjusted net present value: What is the current valuation of Moderna’s MRNA-3705?
Pharmaceutical Technology
NOVEMBER 18, 2023
MRNA-3705 is a gene therapy commercialized by Moderna, with a leading Phase II program in Methylmalonic Acidemia.
Running Decentralized Trials at Scale: Planning for Success
Advertisement
There’s been a rapid shift towards decentralization in clinical trials & it’s clear why. The potential for reaching a larger pool of recruits is possible when sponsors can bring more trial activities to the patient. Tele visits, digital consent, new monitoring sensors, & direct-to-patient supply are virtual tools that existed before the pandemic, but now there’s swift adoption of these methods because they’ve been proven to help launch & complete trials more effectively.
Amphotericin B by Cystetic Medicines for Cystic Fibrosis: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Amphotericin B is under clinical development by Cystetic Medicines and currently in Phase I for Cystic Fibrosis.
Tusamitamab ravtansine by Sanofi for Endometrial Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Endometrial Cancer.
PF-07257876 by Pfizer for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
PF-07257876 is under clinical development by Pfizer and currently in Phase I for Non-Small Cell Lung Carcinoma.
Tusamitamab ravtansine by Sanofi for Colorectal Cancer: Likelihood of Approval
Pharmaceutical Technology
NOVEMBER 18, 2023
Tusamitamab ravtansine is under clinical development by Sanofi and currently in Phase II for Colorectal Cancer.
Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Let's personalize your content